Intellia Therapeutics presents results from Phase 2 study of NTLA-2002
Intellia Therapeutics (NTLA) announced positive Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary ...
FierceBiotech3h
Poseida's HAE gene therapy edits primate livers and reduces kallikrein protein levels in mice, company says
Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...
Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Following Phase 2 Data Release
Based on these findings, Intellia chose the 50 mg dose for their Phase 3 research, HAELO, which is now under enrollment ...
Intellia data spark debate about CRISPR drug’s potential
Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...
Poseida Therapeutics to present data on P-KLKB1-101 in hereditary angioedema
Poseida Therapeutics (PSTX) announced the upcoming presentation of new preclinical data supporting the potential of P-KLKB1-101, a ...
healthday4h
ACAAI: Gene-Editing Therapy Reduces Angioedema Attacks in Hereditary Angioedema
For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regul ...
technologynetworks4h
CRISPR-Cas9 Therapy Shows Promise As Single-Dose Treatment for Hereditary Angioedema
Researchers expand on their phase one study demonstrating a single treatment with a CRISPR-Cas9-based gene editing therapy, ...
Garrett Motion Inc. (GTX) Q3 2024 Earnings Call Transcript
I would like to welcome everyone to the Garrett Motion Third Quarter 2024 Financial Results Conference Call. This call is being recorded and a replay will be available later today. After the company's ...
CRISPR-Cas9 gene editing trial results support further development as treatment for hereditary angioedema
A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...
Intellia slips after mid-stage data for CRISPR-based hereditary angioedema therapy
Intellia Therapeutics (NTLA) stock fell ~9% in reaction to Phase 2 trial data for a CRISPR-based gene editing therapy for ...
FierceBiotech7h
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks in phase 2
Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...
EurekAlert!8h
Phase Two results with CRISPR-Cas9 gene editing support further development as treatment for hereditary angioedema (HAE)
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...